Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CrystalGenomics To Push Fabl Inhibitor Trials With Govt Support

This article was originally published in PharmAsia News

Executive Summary

Following the positive outcome of a US Phase IIa study for its pioneering Fabl inhibitor, CrystalGenomics plans to proceed with global clinical trials of the first-in-class antibiotic for MRSA in improved dosage forms, with some financial help from South Korea’s government.

You may also be interested in...



Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia

Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.

Korea CDC Promoted To Independent Infectious Disease 'Control Tower' Amid COVID-19

In the midst of the ongoing COVID-19 pandemic, Korea promotes its Centers For Disease Control & Prevention to a central administrative agency that will act as an infectious disease "control tower" that independently carries out investigation and research and sets infectious disease policy. A dedicated vice-minister of health and welfare has also been appointed to step up the public health and medical system. 

Korea Gains Speed In Race For NASH Therapies

NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel